18F-FDG PET/CT for Risk Stratification and Prognosis of Patients with Hypermetabolic Gastrointestinal Stromal Tumors

<b>Objectives:</b> We aimed to evaluate the value of various PET parameters derived from <sup>18</sup>F- FDG PET/CT for risk stratification and prognosis of hypermetabolic gastrointestinal stromal tumors (GISTs). <b>Methods:</b> This study included 43 patients who underwent <sup>18</sup>F-FDG PET/CT imaging with hypermetabolic (SUVmax > 2.5) GIST and underwent surgical treatment. Clinicopathological characteristics, risk stratification, PET parameters including standard uptake values (SUVs), metabolic tumor volume (MTV), total lesion glycolysis (TLG), and heterogeneity index (HI), and follow-up data were reviewed. The relationship between PET parameters and risk stratification based on the modified National Institutes of Health (NIH) criteria was analyzed. PET parameters were assessed to predict relapse-free survival (RFS) and overall survival (OS), based on Cox regression analysis and Kaplan-Meier analysis. <b>Results:</b> The median follow-up duration was 50 months. During follow-up, 11 patients (25.58%) experienced recurrence and 8 (18.60%) died. In risk stratification, the high-risk group exhibited more frequent extragastric location, larger tumor size, higher mitotic count, and elevated PET parameters except SUVmax. MTV (≤32.68 vs. >32.68, 95% CI: 1.358-72.048, <i>p</i> = 0.024) emerged as an independent PET parameter of risk stratification. In univariate analysis, tumor location (gastric vs. extragastric), SUVmax (≤10.25 vs. >10.25), and HI (≤2.44 vs. >2.44) were significant prognostic factors for RFS. Tumor location and SUVmax were significant to OS on univariate analysis. However, in multivariate analysis, only SUVmax (95% CI: 1.549-46.071, <i>p</i> = 0.014) was an independent prognostic factor for both RFS and OS. <b>Conclusions:</b><sup>18</sup>F-FDG PET/CT demonstrates predictive value for hypermetabolic GIST patients. MTV derived from <sup>18</sup>F-FDG PET/CT improves the ability of predicting risk stratification. SUVmax is an effective predictor of both RFS and OS.

Authors

Institutions

Publication Details

Journal
Cancers
Published
2026-02-24
DOI
https://doi.org/10.3390/cancers18050717
Primary Topic
Gastrointestinal Tumor Research and Treatment
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

18F-FDG PET/CT for Risk Stratification and Prognosis of Patients with Hypermetabolic Gastrointestinal Stromal Tumors

Huanyu Chen, Xiaoli Lan, Li Zhang, Jinbo Gui et al.
Cancers
Gastrointestinal Tumor Research and Treatment
article

18F-FDG PET/CT for Risk Stratification and Prognosis of Patients with Hypermetabolic Gastrointestinal Stromal Tumors

Huanyu Chen, Xiaoli Lan, Li Zhang, Jinbo Gui, Yi-Xiang Wang, Yujun Wu, Chunxia Qin, Wei Cao, Yong He, Yu Liu
article en

Abstract

<b>Objectives:</b> We aimed to evaluate the value of various PET parameters derived from <sup>18</sup>F- FDG PET/CT for risk stratification and prognosis of hypermetabolic gastrointestinal stromal tumors (GISTs). <b>Methods:</b> This study included 43 patients who underwent <sup>18</sup>F-FDG PET/CT imaging with hypermetabolic (SUVmax > 2.5) GIST and underwent surgical treatment. Clinicopathological characteristics, risk stratification, PET parameters including standard uptake values (SUVs), metabolic tumor volume (MTV), total lesion glycolysis (TLG), and heterogeneity index (HI), and follow-up data were reviewed. The relationship between PET parameters and risk stratification based on the modified National Institutes of Health (NIH) criteria was analyzed. PET parameters were assessed to predict relapse-free survival (RFS) and overall survival (OS), based on Cox regression analysis and Kaplan-Meier analysis. <b>Results:</b> The median follow-up duration was 50 months. During follow-up, 11 patients (25.58%) experienced recurrence and 8 (18.60%) died. In risk stratification, the high-risk group exhibited more frequent extragastric location, larger tumor size, higher mitotic count, and elevated PET parameters except SUVmax. MTV (≤32.68 vs. >32.68, 95% CI: 1.358-72.048, <i>p</i> = 0.024) emerged as an independent PET parameter of risk stratification. In univariate analysis, tumor location (gastric vs. extragastric), SUVmax (≤10.25 vs. >10.25), and HI (≤2.44 vs. >2.44) were significant prognostic factors for RFS. Tumor location and SUVmax were significant to OS on univariate analysis. However, in multivariate analysis, only SUVmax (95% CI: 1.549-46.071, <i>p</i> = 0.014) was an independent prognostic factor for both RFS and OS. <b>Conclusions:</b><sup>18</sup>F-FDG PET/CT demonstrates predictive value for hypermetabolic GIST patients. MTV derived from <sup>18</sup>F-FDG PET/CT improves the ability of predicting risk stratification. SUVmax is an effective predictor of both RFS and OS.

CancersVol. 18(5)
Union Hospital (HK), China Three Gorges University (CN), Wuhan University (CN), State Key Laboratory of Information Engineering in Surveying Mapping and Remote Sensing (CN), Zhongnan Hospital of Wuhan University (CN), Huazhong University of Science and Technology (CN)
Good health and well-being
Openalex Percentile: Top 43%
Gastrointestinal Tumor Research and Treatment
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.